Bayer is still facing tens of thousands of active lawsuits in 2026. The company has already paid more than $10 billion to settle Roundup cancer claims alone, but new cases keep coming.
If you used Roundup and got diagnosed with cancer, you may still have time to file. The same goes for people harmed by Essure, Xarelto, or PCB contamination tied to Bayer products.
This article covers every active Bayer lawsuit in 2026. You will learn who qualifies, how much people are getting paid, what deadlines matter, and how recent court rulings affect your rights.
One fact that surprises most people: Bayer set aside an extra $6.9 billion just for future Roundup claims. That money is waiting.
Bayer Lawsuit 2026: Where Things Stand Right Now
Bayer faces active litigation on multiple fronts heading into 2026, with Roundup cancer claims still dominating the company’s legal exposure. The German pharmaceutical and chemical giant has now spent years fighting and settling cases tied to products it manufactures or inherited through its 2018 acquisition of Monsanto for $63 billion.
As of early 2026, roughly 50,000 to 60,000 Roundup lawsuits remain pending or unresolved. Bayer has resolved over 100,000 Roundup claims through settlements, but the pipeline of new filings has not slowed down.
Beyond Roundup, Bayer continues to deal with lawsuits over its Essure birth control device, its blood thinner Xarelto, and environmental contamination from PCBs (polychlorinated biphenyls) produced by Monsanto decades ago.
| Bayer Lawsuit Category | Status in 2026 | Estimated Claims |
|---|---|---|
| Roundup (cancer) | Active, settling | 50,000+ pending |
| Essure (device injury) | Mostly settled | Limited new claims |
| Xarelto (blood thinner) | Settled, some pending | Few remaining |
| PCB contamination | Active litigation | Thousands |
The company’s total legal reserves for all product liability cases exceed $16 billion. That figure keeps climbing. Bayer’s stock price has reflected the ongoing legal pressure, dropping significantly since the Monsanto deal closed.
For affected consumers, 2026 represents a window. Many claims are still open. Deadlines have not passed in most states. The door is not closed yet.
Bayer Roundup Lawsuit: The Biggest Case Against Bayer
The Bayer Roundup lawsuit is the largest mass tort in Bayer’s history and one of the biggest in American legal history. At its core, plaintiffs claim that Roundup’s active ingredient, glyphosate, causes cancer, specifically non-Hodgkin lymphoma.
This litigation started gaining traction after the International Agency for Research on Cancer (IARC), a branch of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” in March 2015. Monsanto owned Roundup at the time. Bayer inherited the legal mess when it bought Monsanto.
The first major trial verdict came in August 2018. A California jury awarded school groundskeeper Dewayne Johnson $289 million after he developed non-Hodgkin lymphoma from years of Roundup use. That verdict was later reduced to $78 million but sent shockwaves through the legal world.
Two more bellwether trials followed:
- Edwin Hardeman received a $80 million jury verdict in March 2019
- Alva and Alberta Pilliod won a $2 billion verdict in May 2019, later reduced to $87 million
These early wins opened the floodgates. Tens of thousands of plaintiffs filed claims. The cases were consolidated into MDL 2741 in the U.S. District Court for the Northern District of California under Judge Vince Chhabria.
Bayer initially denied any link between Roundup and cancer. The company has since shifted its strategy, choosing to settle most claims rather than risk more jury verdicts.
Bayer Roundup Settlement: How Much Has Been Paid
Bayer has paid approximately $10.9 billion in Roundup settlements since 2020. That figure covers the bulk of resolved claims from the first wave of litigation.
In June 2020, Bayer announced a $10.9 billion settlement agreement to resolve roughly 100,000 pending Roundup cases. The deal was structured in tiers, with individual payouts varying based on the severity of the plaintiff’s cancer and strength of their exposure evidence.
Not every claim has been paid yet. Settlement processing takes time. Some claimants received checks within months. Others waited more than a year.
| Settlement Detail | Amount/Status |
|---|---|
| Total announced (2020) | $10.9 billion |
| Claims resolved | ~100,000+ |
| Additional reserve (2024) | $6.9 billion |
| Average individual payout | $5,000 to $250,000+ |
| Highest individual settlements | $1 million+ (severe cases) |
Bayer also set aside an additional $6.9 billion for future Roundup claims in its 2024 financial disclosures. This reserve acknowledges that new plaintiffs keep filing.
The settlement did not require Bayer to admit wrongdoing. It did not require removing Roundup from the market. The product is still sold today, though Bayer announced plans to replace glyphosate in residential Roundup products by 2023, a move that has been partially implemented.
For people who have not yet filed, the settlement fund for future claims remains active. The window is narrowing, but it has not closed.
Key Takeaway: Bayer has paid over $10 billion in Roundup settlements and reserved billions more for future claims, but tens of thousands of cases remain open in 2026.
Bayer Lawsuit Payout: What Claimants Are Receiving
Bayer lawsuit payouts range from a few thousand dollars to well over a million, depending on the specific case and product involved. Roundup cancer claims make up the vast majority of payouts.
The typical Roundup settlement payout falls between $5,000 and $250,000. Cases involving severe cancer, long-term Roundup exposure, and strong medical documentation tend to land at the higher end.
Some factors that affect your payout:
- Type of cancer diagnosed (non-Hodgkin lymphoma pays the most)
- Duration of Roundup exposure (years of regular use increases value)
- Medical records linking diagnosis to glyphosate exposure
- Age at diagnosis and overall health impact
- Whether you went to trial or settled
People who refused to settle and went to trial have won much larger verdicts. But trials carry risk. You could win big or get nothing.
| Payout Tier | Estimated Range | Typical Case Profile |
|---|---|---|
| Tier 1 (low) | $5,000 to $25,000 | Mild exposure, limited records |
| Tier 2 (mid) | $25,000 to $150,000 | Moderate exposure, clear diagnosis |
| Tier 3 (high) | $150,000 to $500,000 | Heavy exposure, aggressive cancer |
| Tier 4 (severe) | $500,000 to $2 million+ | Terminal cases, wrongful death |
Attorney fees typically consume 30% to 40% of the settlement. That is standard in contingency-based mass tort cases. Make sure you understand the fee structure before signing with any law firm.
Essure and Xarelto payouts are separate and generally smaller, ranging from a few thousand to $50,000 in most resolved cases.
Bayer Roundup Cancer Settlement Amounts by Case Type
Bayer Roundup cancer settlement amounts vary significantly based on diagnosis type, case strength, and whether the claim went through the settlement program or a jury trial. Not all cancer diagnoses receive the same value.
Non-Hodgkin lymphoma (NHL) is the primary cancer linked to Roundup in the litigation. Within NHL, several subtypes appear in the claims:
- Diffuse large B-cell lymphoma (DLBCL): most common subtype in claims
- Follicular lymphoma: second most common
- Chronic lymphocytic leukemia (CLL): accepted in some claims
- Mantle cell lymphoma: less common but eligible
- Hairy cell leukemia: included in certain settlement tiers
| Cancer Type | Typical Settlement Range | Notes |
|---|---|---|
| DLBCL | $75,000 to $300,000 | Strongest link to glyphosate |
| Follicular lymphoma | $50,000 to $200,000 | Well-documented in studies |
| CLL/SLL | $25,000 to $150,000 | Accepted but lower tier |
| Other NHL subtypes | $10,000 to $100,000 | Case-by-case evaluation |
| Wrongful death (any NHL) | $150,000 to $2 million+ | Depends on family circumstances |
Plaintiffs with a confirmed NHL diagnosis, documented Roundup use spanning multiple years, and medical expert testimony tying the two together consistently receive higher settlement offers.
Cases where the plaintiff died from cancer before the claim was resolved often receive priority processing and higher compensation. Surviving family members can file wrongful death claims on behalf of the deceased.
Bayer Cancer Lawsuit: Linking Roundup to Non-Hodgkin Lymphoma
The Bayer cancer lawsuit rests on one central claim: that long-term exposure to Roundup’s glyphosate causes non-Hodgkin lymphoma. This link has been argued in courtrooms, debated by scientists, and tested by juries.
The scientific foundation started with the IARC’s 2015 classification of glyphosate as a Group 2A carcinogen, meaning “probably carcinogenic to humans.” IARC reviewed published studies on glyphosate exposure in agricultural workers and found increased rates of non-Hodgkin lymphoma.
Bayer has consistently pointed to other regulatory bodies, including the U.S. Environmental Protection Agency (EPA), which has stated that glyphosate is “not likely to be carcinogenic to humans.” This conflicting science has been a central battle in every trial.
Three juries heard the evidence and sided with the plaintiffs. Each found that Roundup was a substantial factor in causing cancer.
Key scientific evidence used in trials:
- Agricultural Health Study data on farmer cancer rates
- Meta-analyses showing 41% increased lymphoma risk in heavy glyphosate users
- Monsanto internal emails suggesting the company ghostwrote safety studies
- Expert epidemiologist testimony linking exposure to diagnosis
The internal documents proved especially damaging. Emails showed Monsanto employees discussing strategies to influence scientific literature and discredit IARC findings. Jurors in the Johnson trial called this evidence “shocking.”
For plaintiffs filing in 2026, the science has only gotten stronger. More independent studies have been published since 2020 supporting the cancer link.
Key Takeaway: Three separate juries found that Roundup causes cancer, and the scientific evidence supporting that link has grown stronger since the first trial verdict in 2018.
Bayer Glyphosate Lawsuit: The Science Behind the Claims
The Bayer glyphosate lawsuit centers on whether this widely used herbicide causes cancer in humans. Glyphosate is the active ingredient in Roundup and the most used agricultural chemical in the world.
More than 250 million pounds of glyphosate are sprayed on American crops, lawns, and landscapes each year. It has been used commercially since 1974. Billions of people have been exposed to some level of glyphosate through food, water, or direct contact.
The scientific debate breaks down along clear lines:
| Organization | Position on Glyphosate |
|---|---|
| IARC (WHO) | Probably carcinogenic (Group 2A) |
| U.S. EPA | Not likely carcinogenic |
| European Food Safety Authority | No cancer concern at current exposure levels |
| California OEHHA | Listed as known carcinogen (Prop 65) |
Plaintiffs argue that the EPA’s position was influenced by Monsanto’s lobbying and ghostwritten studies. Court documents revealed that a senior EPA official allegedly helped Monsanto “kill” a separate agency’s glyphosate review.
Independent academic research published between 2019 and 2025 has consistently found elevated cancer risk among people with heavy glyphosate exposure. A 2019 meta-analysis published in Mutation Research found a 41% increased risk of non-Hodgkin lymphoma.
Bayer announced in 2021 that it would remove glyphosate from residential Roundup products sold in the U.S. by 2023. The agricultural and commercial versions still contain glyphosate. This move was described as a business decision, not an admission of health risk.
The distinction matters for 2026 claims. If you used the older glyphosate-based Roundup, your exposure history is exactly what attorneys are looking for.
Bayer Class Action Lawsuit: Individual vs. Mass Claims
The Bayer class action lawsuit is a term people commonly search, but most Bayer litigation is actually structured as a mass tort, not a traditional class action. Understanding this difference matters for your payout.
In a class action, one lawsuit represents everyone. One settlement amount gets split among all class members. You might get $50 or $200 from a class action.
In a mass tort, each person files their own individual lawsuit. Your case is evaluated on its own facts. Your payout is based on your specific injuries, exposure, and damages.
| Feature | Class Action | Mass Tort (Bayer Roundup) |
|---|---|---|
| Individual evaluation | No | Yes |
| Payout per person | Small ($10 to $500) | Large ($5,000 to $2M+) |
| You need your own evidence | No | Yes |
| Settlement varies by person | No | Yes |
| Attorney represents you individually | No | Yes |
Bayer Roundup cases are consolidated in MDL 2741 for pretrial purposes. This means thousands of individual lawsuits are grouped together for efficiency, but each case retains its own identity.
Some smaller Bayer cases, like certain consumer protection claims, may proceed as actual class actions. But the big-money litigation involving cancer, device injuries, and serious harm is individual.
This is good news for people with strong cases. Your settlement is not diluted by thousands of weaker claims. If you have solid medical records and documented exposure, your case stands on its own merits.
Who Qualifies for a Bayer Lawsuit in 2026
You may qualify for a Bayer lawsuit in 2026 if you used a Bayer product and suffered a specific injury or illness linked to that product. Eligibility depends on the product, your diagnosis, and your state’s statute of limitations.
For Roundup claims, the most common qualifications:
- You used Roundup regularly (at home, at work, or on a farm)
- You were diagnosed with non-Hodgkin lymphoma or a related blood cancer
- Your diagnosis came after a period of Roundup exposure
- You have medical records supporting your cancer diagnosis
- Your state’s filing deadline has not passed
For Essure claims:
- You had the Essure device implanted
- You experienced complications like chronic pain, device migration, organ perforation, or unintended pregnancy
- You required surgery to remove the device
For Xarelto claims:
- You took Xarelto and experienced serious bleeding events
- Most Xarelto cases have already been settled, but some remain
| Product | Key Qualification | Primary Injury |
|---|---|---|
| Roundup | Regular use + cancer diagnosis | Non-Hodgkin lymphoma |
| Essure | Device implanted + complications | Pain, perforation, migration |
| Xarelto | Took medication + bleeding event | Uncontrolled bleeding |
| PCBs | Lived near contaminated site | Environmental health damage |
You do not need to have purchased Roundup yourself to qualify. Agricultural workers, landscapers, groundskeepers, and even family members who handled contaminated clothing have filed successful claims.
The critical factor is timing. Each state sets its own deadline for filing personal injury and product liability claims. In most states, you have two to three years from the date of diagnosis.
Key Takeaway: If you used Roundup and developed non-Hodgkin lymphoma, you likely qualify to file a claim in 2026, but your state’s deadline determines how much time you have left.
Bayer Roundup Lawsuit Update 2026: Latest Court Rulings
The Bayer Roundup lawsuit in 2026 continues to produce new rulings, settlements, and legal developments. The most significant recent event was the U.S. Supreme Court’s decision in 2024 to deny Bayer’s petition for certiorari in the Hardeman case.
That denial was a massive blow to Bayer. The company had argued that federal pesticide labeling law preempted state-level failure-to-warn claims. If the Supreme Court had agreed, it could have wiped out thousands of pending cases. Instead, the Court let the lower court ruling stand.
Since that decision, several developments have unfolded:
- New filings surged in late 2024 and into 2025 as plaintiffs gained confidence
- Additional bellwether trials were scheduled in multiple state courts
- Bayer increased its legal reserves to cover the growing case count
- Several states extended their statutes of limitations for toxic exposure claims
In early 2026, settlement negotiations between Bayer and plaintiffs’ attorneys have intensified. Bayer appears motivated to resolve remaining claims without additional trials, which have consistently gone badly for the company.
| Court Event | Date | Impact |
|---|---|---|
| Supreme Court cert denial (Hardeman) | June 2024 | Preserved state-level claims |
| New bellwether trial selections | Late 2025 | Pressure on Bayer to settle |
| Increased legal reserves | 2024-2025 | Signals more payouts coming |
| New state court filings | 2025-2026 | Case count rising again |
For plaintiffs, the legal landscape strongly favors claimants heading into 2026. Every major court decision has gone against Bayer.
Bayer Settlement Update: New Developments This Year
The Bayer settlement update for 2026 shows the company continuing to resolve claims while bracing for new ones. Bayer has publicly stated its goal to resolve the bulk of remaining Roundup litigation within the next few years.
In its latest financial reports, Bayer disclosed total litigation provisions exceeding $16 billion across all product liability matters. The company has been increasing this figure annually as new claims arrive.
Key settlement developments in 2025 and early 2026:
- Bayer accelerated payments to claimants who had been waiting since the 2020 settlement
- The company entered new round of negotiations with plaintiffs’ steering committee in MDL 2741
- State court settlements in Missouri, California, and Pennsylvania moved forward independently
- Bayer’s proposed “science panel” approach to future claims (rejected in 2021) was not revived
Bayer’s financial filings show the company paid out approximately $1.5 to $2 billion per year in Roundup settlements from 2021 through 2025. That pace is expected to continue or increase in 2026.
| Year | Estimated Roundup Payouts |
|---|---|
| 2020-2021 | ~$4 billion |
| 2022 | ~$2 billion |
| 2023 | ~$1.8 billion |
| 2024 | ~$1.5 billion |
| 2025 | ~$1.7 billion (estimated) |
| 2026 | $1.5 to $2 billion (projected) |
The company has not announced any plan to stop accepting or resolving claims. Bayer’s CEO has acknowledged on earnings calls that Roundup litigation will remain a financial drag for years.
Bayer Essure Lawsuit: Birth Control Device Injuries
The Bayer Essure lawsuit involves a permanent birth control device that caused severe injuries in thousands of women. Essure was a small metal coil implanted in the fallopian tubes to block pregnancy without surgery.
Bayer acquired Essure through its purchase of Conceptus Inc. The FDA approved the device in 2002. Problems emerged almost immediately, with women reporting:
- Chronic pelvic pain
- Device migration (coils moving to other parts of the body)
- Organ perforation (coils puncturing the uterus or abdomen)
- Unintended pregnancies
- Nickel allergic reactions
- Need for surgical removal (hysterectomy)
The FDA received more than 30,000 adverse event reports about Essure. In 2018, the FDA ordered Bayer to stop selling the device in the United States. Bayer pulled Essure from the market worldwide.
| Essure Lawsuit Detail | Info |
|---|---|
| Device approval | 2002 |
| Market withdrawal | 2018 |
| Adverse event reports | 30,000+ |
| Primary injuries | Pain, perforation, migration |
| Settlement status | Mostly resolved, some pending |
| Typical payout range | $2,000 to $50,000 |
Many Essure lawsuits were resolved through confidential settlements. Bayer did not admit the device was defective. The company maintained that Essure was safe and effective when used as directed.
Filing new Essure claims in 2026 is more difficult. Most statutes of limitations have expired. However, women who only recently discovered their injuries or complications may still have options under the “discovery rule” in their state.
Key Takeaway: Bayer pulled its Essure birth control device from the market in 2018 after 30,000 adverse event reports, and most lawsuits have been settled, though some claims may still be viable in 2026.
Bayer PCB Lawsuit: Environmental Contamination Claims
The Bayer PCB lawsuit targets environmental contamination from polychlorinated biphenyls (PCBs) that Monsanto manufactured for decades before Bayer acquired the company. PCBs are toxic industrial chemicals linked to cancer and other serious health problems.
Monsanto was the sole U.S. manufacturer of PCBs from 1935 until they were banned in 1979. During that time, PCBs were used in electrical equipment, building materials, paints, and other industrial products. These chemicals do not break down naturally. They persist in soil, water, and human tissue for decades.
Bayer inherited this liability through the Monsanto acquisition. Cities, school districts, and municipalities have filed lawsuits seeking cleanup costs and damages.
Notable PCB lawsuits:
- City of Seattle filed suit seeking damages for PCB contamination in stormwater systems
- City of Portland and multiple Oregon entities sued over water system contamination
- School districts nationwide filed claims for PCB removal from old building materials
- State of Washington sued for natural resource damages
| PCB Lawsuit Type | Plaintiffs | Estimated Damages |
|---|---|---|
| Municipal water contamination | City governments | Hundreds of millions |
| School building contamination | School districts | Tens of millions |
| Natural resource damages | State governments | Billions (potential) |
| Individual health claims | Residents near sites | Varies |
PCB litigation is different from the Roundup cases. These are typically government or institutional plaintiffs seeking cleanup costs, not individual consumers seeking personal injury damages.
However, individuals living near heavily contaminated sites may have their own claims. If you were exposed to PCBs through contaminated water, soil, or buildings, consult with a toxic tort attorney about your rights.
Bayer Xarelto Lawsuit: Blood Thinner Side Effects
The Bayer Xarelto lawsuit involved claims that the blood thinner Xarelto (rivaroxaban) caused uncontrollable bleeding events in patients. Bayer and its marketing partner Johnson & Johnson faced thousands of lawsuits from patients who suffered serious harm.
Xarelto was approved by the FDA in 2011 as an anticoagulant to prevent blood clots, stroke, and deep vein thrombosis. The drug was marketed as a convenient alternative to warfarin because it did not require regular blood monitoring.
The problem: when Xarelto caused bleeding, there was no approved antidote to stop it. Patients experienced:
- Gastrointestinal bleeding
- Brain hemorrhages
- Uncontrollable bleeding during surgery
- Fatal bleeding events
At its peak, more than 25,000 Xarelto lawsuits were filed in federal and state courts. The federal cases were consolidated in MDL 2592 in the Eastern District of Louisiana.
| Xarelto Lawsuit Detail | Info |
|---|---|
| Drug approval | 2011 |
| Peak lawsuit count | 25,000+ |
| MDL location | Eastern District of Louisiana |
| Primary injury | Uncontrolled bleeding |
| Settlement status | Largely resolved |
| Estimated total settlements | $775 million+ |
Bayer and Johnson & Johnson agreed to pay approximately $775 million to settle the bulk of Xarelto claims in 2019. Individual payouts were relatively modest compared to Roundup settlements, typically ranging from a few thousand to $30,000.
New Xarelto claims in 2026 are rare. Most statutes of limitations have expired. The drug is still on the market, and an antidote (andexanet alfa, brand name Andexxa) was approved in 2018.
How to File a Bayer Lawsuit: Step by Step
Filing a Bayer lawsuit in 2026 requires gathering evidence, finding qualified legal representation, and meeting your state’s filing deadline. The process is straightforward but time-sensitive.
Here is the step-by-step process:
Step 1: Determine your eligibility. Identify which Bayer product harmed you. Confirm you have a qualifying injury or diagnosis.
Step 2: Gather your evidence. Collect medical records showing your diagnosis. Find proof of product use, such as purchase receipts, employer records, or photographs.
Step 3: Find a mass tort attorney. Look for a law firm experienced in Bayer litigation. Most work on contingency, meaning you pay nothing upfront.
Step 4: File your claim. Your attorney will file the lawsuit in the appropriate court. Roundup cases typically enter MDL 2741 or a state court.
Step 5: Case evaluation. Your claim is reviewed, categorized by severity, and assigned a settlement tier.
Step 6: Negotiate or go to trial. Most cases settle. Some plaintiffs choose to go to trial for a potentially larger award.
| Filing Step | What You Need | Timeline |
|---|---|---|
| Eligibility check | Diagnosis + product use | 1 to 2 weeks |
| Evidence gathering | Medical records, proof of use | 2 to 8 weeks |
| Attorney selection | Consultation (free) | 1 to 2 weeks |
| Filing | Attorney handles paperwork | 1 to 4 weeks |
| Case evaluation | Attorney + defendant review | 3 to 12 months |
| Resolution | Settlement or trial | 6 months to 3 years |
You do not need to go to court in person for most Bayer claims. The majority of mass tort cases settle before trial. Your attorney handles the paperwork and negotiations.
Key Takeaway: Filing a Bayer lawsuit in 2026 starts with confirming your eligibility and gathering medical records, and most attorneys handle these cases on a no-win, no-fee basis.
Bayer Lawsuit Deadline 2026: Key Dates to Know
Bayer lawsuit deadlines in 2026 vary by state, by product, and by when you discovered your injury. Missing your deadline means losing your right to file, permanently. This is called the statute of limitations.
For Roundup cancer claims, the statute of limitations in most states is two to three years from the date of diagnosis. Some states use a “discovery rule,” which starts the clock when you learned (or should have learned) that Roundup caused your cancer.
| State | Statute of Limitations (Personal Injury) | Discovery Rule |
|---|---|---|
| California | 2 years | Yes |
| Texas | 2 years | Yes |
| Florida | 4 years (changed 2024) | Yes |
| New York | 3 years | Yes |
| Illinois | 2 years | Yes |
| Missouri | 5 years | Yes |
| Pennsylvania | 2 years | Yes |
| Ohio | 2 years | Yes |
Some states have recently shortened their filing windows. Florida reduced its statute of limitations from four years to two years for negligence claims in 2024, though some product liability claims may still have longer windows.
Key deadlines to watch in 2026:
- MDL 2741 case management deadlines set by Judge Chhabria
- State-specific filing deadlines based on your diagnosis date
- Settlement claim submission deadlines for existing settlement programs
If you were diagnosed with cancer after using Roundup and have not yet filed, check your state’s deadline immediately. Waiting could cost you everything.
Is Bayer Still Paying Roundup Claims in 2026
Yes, Bayer is still paying Roundup claims in 2026. The company continues to process and pay settlements from both the original 2020 agreement and newer individual case resolutions.
Bayer’s financial disclosures confirm ongoing payments. The company’s 2024 annual report showed litigation-related cash outflows of approximately $1.5 billion for Roundup alone. Similar levels are expected through 2026 and beyond.
Here is what the payment situation looks like:
- Old claims (filed before 2020): Most have been paid or are in final processing
- Claims filed 2020 to 2023: Being processed, many paid, some in disputes
- Claims filed 2024 to 2026: Being evaluated, settlement offers in progress
- New claims: Still being accepted in most states
| Claim Period | Payment Status |
|---|---|
| Pre-2020 filings | Mostly paid |
| 2020 to 2022 filings | Largely resolved |
| 2023 to 2024 filings | Actively being settled |
| 2025 to 2026 filings | In evaluation phase |
Bayer has publicly stated it wants to resolve Roundup litigation “efficiently and fairly.” The company has not set a cutoff date for accepting new claims, though settlement terms may become less favorable as the years pass.
Think of it like catching a sale before it ends. The longer you wait, the less leverage you may have. Early filers in mass torts historically receive better settlement terms than late arrivals.
If you have a valid claim, 2026 is not too late. But it is getting later.
Bayer Roundup Supreme Court Ruling: What It Changed
The Bayer Roundup Supreme Court ruling refers to the Court’s June 2024 decision to deny Bayer’s petition for certiorari in Bayer v. Hardeman. This was the single most important legal moment in the Roundup litigation since the first trial verdict.
Bayer had asked the Supreme Court to rule that federal pesticide labeling law (FIFRA) preempted state failure-to-warn claims. In plain English, Bayer argued that because the EPA approved Roundup’s label, individual states could not require different warnings, and therefore plaintiffs could not sue for inadequate warnings.
If the Court had agreed, it would have effectively killed most pending Roundup lawsuits. The Court declined to hear the case, letting the Ninth Circuit’s ruling in favor of plaintiff Edwin Hardeman stand.
What this ruling changed:
- State-level lawsuits survive. Plaintiffs can continue suing in any state court.
- Bayer’s strongest defense is gone. The preemption argument was Bayer’s best legal weapon.
- New filings increased. Attorneys who were waiting for the ruling began accepting new clients.
- Settlement pressure grew. Without the preemption shield, Bayer has stronger incentive to settle.
| Supreme Court Decision | Details |
|---|---|
| Case | Bayer v. Hardeman |
| Decision | Certiorari denied (case not heard) |
| Date | June 2024 |
| Effect | State failure-to-warn claims preserved |
| Impact on pending cases | All remain active |
| Impact on new filings | Encouraged surge in new claims |
Some legal analysts had expected the Court to take the case, given Bayer’s aggressive lobbying effort. The denial surprised many and was widely seen as a victory for consumer rights.
For people considering filing in 2026, this ruling removed the biggest legal obstacle. Your state-level claim is on solid ground.
Key Takeaway: The Supreme Court’s refusal to hear Bayer’s preemption argument in 2024 was the most significant legal win for Roundup plaintiffs, clearing the path for ongoing and new claims in 2026.
Frequently Asked Questions
How much money can I get from a Bayer Roundup lawsuit?
Most Roundup settlements range from $5,000 to $250,000 per person.
Severe cases involving terminal cancer or wrongful death can exceed $1 million.
Your payout depends on your diagnosis, exposure history, and the strength of your medical evidence.
Is it too late to file a Bayer lawsuit in 2026?
It is not too late for most people, but your state’s statute of limitations controls the deadline.
Most states allow two to three years from the date of diagnosis to file.
Check your state’s specific deadline because some have recently shortened their filing windows.
Does Bayer still have to pay Roundup cancer claims?
Yes, Bayer is actively paying Roundup claims in 2026.
The company has reserved more than $16 billion for litigation costs and continues to settle cases.
Payment processing for new claims typically takes 6 to 18 months after filing.
What cancers qualify for a Bayer Roundup settlement?
Non-Hodgkin lymphoma (NHL) is the primary qualifying cancer.
Subtypes like diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia are all eligible.
Other blood cancers may qualify on a case-by-case basis.
How long does it take to get paid from a Bayer lawsuit?
The typical timeline from filing to payment is 12 to 24 months.
Some claims resolve faster if the evidence is strong and the case settles quickly.
Complex cases or those headed to trial can take three years or longer.
This is not a situation where you can afford to sit around. Bayer is still paying claims, the courts have sided with plaintiffs repeatedly, and the science supporting these cases gets stronger every year.
If you think you qualify for any Bayer lawsuit, start gathering your medical records and proof of product use now. Find an experienced mass tort attorney who works on contingency.
The clock is ticking on filing deadlines in every state. Act before your window closes.
